NCT06416007 Lattice Radiotherapy for Dose-Escalated Palliation of Bulky Tumors
| NCT ID | NCT06416007 |
| Status | Recruiting |
| Phase | Phase 2 |
| Sponsor | University of Cincinnati |
| Condition | Cancer |
| Study Type | INTERVENTIONAL |
| Enrollment | 37 participants |
| Start Date | 2024-08-02 |
| Primary Completion | 2027-01-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
In Phase 2, researchers evaluate early signs of effectiveness. You may be randomized to receive the active treatment or a comparator. Monitoring continues closely.
This trial targets 37 participants in total. It began in 2024-08-02 with a primary completion date of 2027-01-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this research study is to determine if lattice radiation therapy (LRT) will provide better treatment for bulky (large) tumors than current standard of care radiotherapy.
Eligibility Criteria
Inclusion Criteria: * Solid tumor malignancy with a clinical indication for radiation * Patients must have measurable disease * Target lesion(s) which are amenable to lattice therapy plan * When applicable, target lesion for radiation amenable to immobilization during delivery of radiotherapy * Age ≥18 years. * ECOG Performance status ≤2 * Life expectancy greater than 3 months * Women of child-bearing potential and men must agree to avoid conception via abstinence (ideal) or a method of birth control (e.g., hormonal or barrier method of birth control) prior to study entry and for at least 30 days after completion of lattice therapy administration. * Ability to understand and the willingness to sign a written informed consent document Exclusion Criteria: * Patients receiving cytotoxic chemotherapy or known radiosensitizing agents within 5 days before or after lattice therapy. * Patients with hematologic malignancies including lymphoma and leukemia as well as primary or metastatic central nervous system (CNS) malignancies. * Patients with a history of conditions which predispose them to increased radiation toxicity * Patients with known contraindications to radiation therapy * Patients with uncontrolled intercurrent illness * Pregnant women
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06416007 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06416007 trial and what does that mean for participants?
Phase 2 trials evaluate whether the treatment shows signs of effectiveness while continuing to monitor safety. More participants are enrolled than in Phase 1 to help refine the treatment protocol.
Is NCT06416007 currently recruiting?
Yes, NCT06416007 is actively recruiting participants. Contact the research team at cancer@uchealth.com for enrollment information.
Where is the NCT06416007 trial being conducted?
This trial is being conducted at Cincinnati, United States.
Who is sponsoring the NCT06416007 clinical trial?
NCT06416007 is sponsored by University of Cincinnati. The trial plans to enroll 37 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.